IPR News

Protecting pharmaceutical and biotechnology inventions in Europe

1

The focused seminar on “Protecting pharmaceutical and biotechnology inventions in Europe”, specifically organised for experts and practitioners in this field, was co-organised by the European Business and Technology Centre (EBTC), the European Patent Office (EPO), the Association of Biotechnology-Led Enterprises (ABLE) and the Council of EU Chambers of Commerce in India (CEUCCI) in Mumbai on 30 March 2017. The event was specifically designed for IP practitioners and industry experts based in Mumbai. It put a special focus on the EPO’s practice in the field of pharmaceuticals and biotechnology, and on practical issues related to filing and prosecution at EPO. 

          

In his welcome address, Mr. Poul V. Jensen, EBTC Director, provided insights on how EBTC is promoting and indigenising European technologies as well as innovations to suit the local needs in India through various projects, programmes and initiatives, enabling Indo-European collaborations. Dr A. Stamatopoulos, Principal Director Biotechnology at EPO, presented a brief overview of the latest developments at the European Patent Office. ABLE’s Chief Operating Officer, Mr. Narayanan Suresh, shed light on the activities pursued by his association and how ABLE is addressing challenges and issues faced by companies in the pharmaceuticals and biotechnology sector. ABLE is a not-for-profit pan-India organisation that represents the Indian biotechnology sector. It has over 400 members from across India representing all verticals of the sector like agribiotech, bio-pharma, industrial biotech and bioinformatics. The Director of the Council of EU Chambers of Commerce in India (CEUCCI), Dr Renu Shome, deliberated on European initiatives to foster Indo-European collaboration. She highlighted that CEUCCI is an important link between European Union-Indian Businesses. CEUCCI organises events and business seminars so that businesses from both regions can interact regularly. 

The technical sessions were moderated by Mr Nicholas Körnig, International Co-operation Administrator from EPO. The seminar addressed the following topics: European Patent Office and the European patent system; the procedures at the EPO from filing to appeal; what is and what is not patentable in the fields of pharmaceuticals and biotechnology with practical examples; procedural and patentability aspects of the grant and opposition procedure at the EPO; and practical experiences in protecting pharma and biotech inventions from India in Europe. The speakers were: Dr. Dieter Tzschoppe, Director Pharmaceuticals, Mr. Klaus-Peter Döpfer, Director Biotechnology and Mr. Durgesh Mukharya, Partner, K&S Partners. 

           

The presentations were followed by a very interactive consultation with the EPO experts. In general, the participants expressed a need for more regular updates about the latest developments in the European patent system and their appreciation of the EPO’s efforts to address timeliness and costs through the “Early Certainty” initiative and the implementation of the upcoming Unitary patent system. 

           

The event was attended by more than 50 senior representatives from law firms, industry experts, as well as IP and trade counsellors from EU Embassies.

The seminar’s content and the EPO efforts have been very much appreciated by the participants and the law firms they represent. They expressed the wish to organise further seminars of this kind with a clear focus on specific domains in the future.

The seminar was organized within the framework of the EPO/EBTC co-operation programme to foster IPR co-operation between Europe and India.  

EPO Practices and Procedures in the Field of Pharmaceuticals and Biotechnology - EPO seminar for Patent Attorneys, New Delhi

1

The European Business and Technology Centre (EBTC) and the European Patent Office (EPO) co-organised a focused seminar on “EPO Practices and Procedures in the Field of Pharmaceuticals and Biotechnology”, in New Delhi on 27th March 2017. The event was specifically designed for IP practitioners and industry experts based in Delhi and the National Capital Region (NCR). It put a special focus on the European practices in the pharmaceutical and biotechnology domain.

          

The presentations were followed by a very interactive discussion. The participants expressed in particular the need to increase awareness about the EPO Guidelines for Examination as well as the instructions on the practices and procedures which are followed in the various aspects of the examination.
After a welcome address by Mr. Poul Jensen, EBTC Director, the leading EPO experts on the subject matter, Dr. A. Stamatopoulos, Principal Director Biotechnology / PAOC, Dr. Dieter Tzschoppe, Director Pharmaceuticals, and Mr. Klaus-Peter Döpfer, Director Biotechnology, gave three very insightful presentations on latest developments at the EPO, patentable  and non-patentable subject matter in the fields of pharmaceuticals and biotechnology  including   procedural and patentability aspects of the grant and opposition      procedure at the EPO for applications and patents relating to pharmaceuticals and biotechnology.

 

The event was attended by 32 senior representatives from law firms and IP counsellors.

 

         Group photo of the seminars attendees

The seminar’s content and the efforts by the EPO have been very much appreciated by the participants and the law firms they represent. They expressed the wish to organise further seminars of this kind with a clear focus on specific domains in the future.

The seminar was organized within the frame of the EPO/EBTC activities in Indo-European cooperation for intellectual property rights (IPR), as EBTC is the official implementation partner of the European Patent Office (EPO) in India.

Protecting pharmaceuticals and biotechnology inventions in Europe

1

In view of the changing scenario of IP in India and the increasing number of international patent filings by Indian biotech and pharma companies, IP practitioners and experts, whether in private practice or industry, should be familiar with the latest developments at the EPO – the patent office for Europe - as far as filing, prosecution and examination procedures and practices in the field of pharma/biotech are concerned.

The seminar will provide a unique opportunity to gain a deep insight into the Pharma/Biotech practice in Europe and to interact with leading EPO experts on the subject matter, in particular Dr. A. Stamatopoulos, Principal Director Biotechnology / PAOC, Dr Dieter Tzschoppe, Director Pharma, and Mr. Klaus-Peter Döpfer, Director Biotechnology.

The event is co-organised by the European Business Technology Centre (EBTC), the European Patent Office (EPO) and the Association of Biotechnology-Led Enterprises (ABLE)

There is no registration fee, but places are limited, and we would therefore appreciate to receive your nominations by return e-mail before 10 March on This email address is being protected from spambots. You need JavaScript enabled to view it. .

Additional information